Buy Rating on Aura Biosciences Inc. Driven by Promising Pipeline and Strategic Expansion in Ocular Oncology
I'm PortAI, I can summarize articles.
Analyst Oliver McCammon from LifeSci Capital maintains a Buy rating on Aura Biosciences Inc., citing a promising pipeline and strategic expansion in ocular oncology. The company's bel-sar therapy shows potential in treating ocular oncology and bladder cancer. Positive Phase 3 trial results for choroidal melanoma are expected by Q4 2027. Aura's expansion into other ocular oncology indications aims to address a substantial market need, reinforcing growth potential. H.C. Wainwright also reiterated a Buy rating with a $22.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments